Skip to main content
SpringerLink
Log in

Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models

  • Protocol
  • First Online:
Ebolaviruses

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1628))

Abstract

Several ebolavirus species, with varying lethality rates, have caused sporadic outbreaks in Africa resulting in human disease. Ebolaviruses also have the potential for use as biological weapons. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse of ebolaviruses. Vaccine or therapeutic efficacy testing of medical countermeasures against ebolaviruses requires an animal model of disease; in vitro testing in cell culture cannot reproduce the complicated balance between host-pathogen interactions required for the ultimate licensure of a countermeasure. Depending on the target of the countermeasure, demonstration of efficacy in the nonhuman primate ebolavirus disease models will most likely be required before licensure. Here, we describe the selection and use of nonhuman primates for vaccine and therapeutic studies against ebolaviruses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Feldmann H, Sanchez A, Geisbert TW (2013) Filoviridae: Ebola and Marburg viruses. In: Knipe DM, Howley P (eds) Fields virology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, PA

    Google Scholar 

  2. Volchkova VA, Feldmann H, Klenk HD, Volchkov VE (1998) The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250(2):408–414. doi:10.1006/viro.1998.9389. [pii] S0042-6822(98)99389-8

    Article  CAS  PubMed  Google Scholar 

  3. Mehedi M, Falzarano D, Seebach J, Hu X, Carpenter MS, Schnittler HJ, Feldmann H (2011) A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 85(11):5406–5414. doi:10.1128/JVI.02190-10. [pii] JVI.02190-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. UDoHaHS (DHHS) (2014) Guidance for industry: product development under the animal rule. UDoHaHS, Silver Spring, MD

    Google Scholar 

  5. Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW (2016) The domestic ferret (mustela putorius furo) as a lethal infection model for 3 species of ebolavirus. J Infect Dis. doi:10.1093/infdis/jiw209

    PubMed Central  Google Scholar 

  6. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178(3):651–661

    Article  CAS  PubMed  Google Scholar 

  7. Bray M, Hatfill S, Hensley L, Huggins JW (2001) Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 125(4):243–253. doi:10.1053/jcpa.2001.0503. [pii] S0021-9975(01)90503-1

    Article  CAS  PubMed  Google Scholar 

  8. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB (1999) Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 179(Suppl 1):S203–S217. doi:10.1086/514305

    Article  PubMed  Google Scholar 

  9. Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, Rosenke R, Long D, Haddock E, Fischer E, Kawaoka Y, Feldmann H (2013) A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 207(2):306–318. doi:10.1093/infdis/jis626. [pii] jis626

    Article  CAS  PubMed  Google Scholar 

  10. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB (2002) Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8(5):503–507

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ryabchikova E, Kolesnikova L, Smolina M, Tkachev V, Pereboeva L, Baranova S, Grazhdantseva A, Rassadkin Y (1996) Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol 141(5):909–921

    Article  CAS  PubMed  Google Scholar 

  12. Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, Reed DK, VanTongeren SA, Mech CA, Bavari S (2009) Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 83(13):6404–6415. doi:10.1128/JVI.00126-09. [pii] JVI.00126-09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Carrion R Jr, Ro Y, Hoosien K, Ticer A, Brasky K, de la Garza M, Mansfield K, Patterson JL (2011) A small nonhuman primate model for filovirus-induced disease. Virology 420(2):117–124. doi:10.1016/j.virol.2011.08.022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Davis KJ, Anderson AO, Geisbert TW, Steele KE, Geisbert JB, Vogel P, Connolly BM, Huggins JW, Jahrling PB, Jaax NK (1997) Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med 121(8):805–819

    CAS  PubMed  Google Scholar 

  15. Geisbert TW, Jahrling PB, Larsen T, Davis KJ, Hensley LE (2004) Filovirus pathogenesis in nonhuman primates. In: Klenk HD, Feldmann H (eds) Ebola and Marburg viruses: molecular and cellular biology. Horizon Bioscience, Norfolk, pp 203–238

    Google Scholar 

  16. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK (2011) Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 13(11):930–936. doi:10.1016/j.micinf.2011.05.002

    Article  PubMed  Google Scholar 

  17. Trefry JC, Wollen SE, Nasar F, Shamblin JD, Kern SJ, Bearss JJ, Jefferson MA, Chance TB, Kugelman JR, Ladner JT, Honko AN, Kobs DJ, Wending MQ, Sabourin CL, Pratt WD, Palacios GF, Pitt ML (2015) Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-u editing site populations in the exposure material. Viruses 7(12):6739–6754. doi:10.3390/v7122969

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Volchkova VA, Dolnik O, Martinez MJ, Reynard O, Volchkov VE (2011) Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J Infect Dis 204(Suppl 3):S941–S946. doi:10.1093/infdis/jir321. [pii] jir321

    Article  CAS  PubMed  Google Scholar 

  19. National Research Council (2011) Guide for the care and use of laboratory animals, 8th edn. The National Academies Press, Washington, DC

    Google Scholar 

  20. Geisbert TW, Strong JE, Feldmann H (2015) Considerations in the use of nonhuman primate models of ebola virus and marburg virus infection. J Infect Dis 212(Suppl 2):S91–S97. doi:10.1093/infdis/jiv284

    Article  PubMed  PubMed Central  Google Scholar 

  21. Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A (2015) Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest 125(8):3241–3255. doi:10.1172/JCI81532

    Article  PubMed  PubMed Central  Google Scholar 

  22. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP (2012) Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Science Transl Med 4(138):138ra181. doi:10.1126/scitranslmed.3003876

    Article  Google Scholar 

  23. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47–53. doi:10.1038/nature13777

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW (2015) Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521(7552):362–365. doi:10.1038/nature14442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H (2011) Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 204(Suppl 3):S1082–S1089. doi:10.1093/infdis/jir350

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW (2013) Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis 7(12):e2600. doi:10.1371/journal.pntd.0002600

    Article  PubMed  PubMed Central  Google Scholar 

  27. Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM 3rd, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, Nau GJ, Spiropoulou C, Nichol ST, Stroher U (2016) Ebola virus persistence in semen of male survivors. Clin Infect Dis 62(12):1552–1555. doi:10.1093/cid/ciw202

    Article  PubMed  Google Scholar 

  28. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Stroher U, Uyeki TM, Ribner BS, Yeh S (2015) Persistence of ebola virus in ocular fluid during convalescence. N Engl J Med 372(25):2423–2427. doi:10.1056/NEJMoa1500306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA

    Chad E. Mire & Thomas W. Geisbert

  2. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA

    Chad E. Mire & Thomas W. Geisbert

Authors
  1. Chad E. Mire
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas W. Geisbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas W. Geisbert .

Editor information

Editors and Affiliations

  1. Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany

    Thomas Hoenen

  2. Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany

    Allison Groseth

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Mire, C.E., Geisbert, T.W. (2017). Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models. In: Hoenen, T., Groseth, A. (eds) Ebolaviruses. Methods in Molecular Biology, vol 1628. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7116-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7116-9_24

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7115-2

  • Online ISBN: 978-1-4939-7116-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation